No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease-Reference-Cited by-同舟云学术

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease

Published:2003-09 Issue:9 Volume:17 Page:1827-1833
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hast R,Hellström-Lindberg E,Ohm L,Björkholm M,Celsing F,Dahl I-M,Dybedal I,Gahrton G,Lindberg G,Lerner R,Linder O,Löfvenberg E,Nilsson-Ehle H,Paul C,Samuelsson J,Tangen J-M,Tidefelt U,Turesson I,Wahlin A,Wallvik J,Winquist I,Öberg G,Bernell P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2403035.pdf

Reference36 articles.

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelo-dysplastic syndromes. Blood 1997; 89: 2079–2088.

2. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326–2331.

3. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F . Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497–501.

4. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French–American–British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol 1996; 14: 2486–2494.

5. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M . Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969–2977.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity;Leukemia;2016-06-15

2. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy;Oncotarget;2016-03-03

3. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes;Cochrane Database of Systematic Reviews;2016-02-16

4. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013);Annals of Hematology;2015-09-26

5. Side Effects of Cytokines Approved for Therapy;Drug Safety;2014-10-01